Automata bets pharma will run wet labs on one AI-ready automation platform

Automata, founded in London in 2015, builds lab automation for life sciences. Its platform combines LINQ, cloud-based orchestration software that integrates instruments and lets users design, schedule and run multistep workflows, with modular robotic benches that physically move labware across a lab; the company says the platform is the reference architecture for autonomous wet labs, making experiments programmable, repeatable and AI-ready. Instruments from Danaher's Beckman Coulter Life Sciences and Molecular Devices now integrate with LINQ.

That life-science labs will buy one software-defined platform — modular robots plus orchestration — making wet labs programmable, repeatable and AI-ready.

$45M Series C announced January 29, 2026, led by Dimension with Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First. Danaher Corporation made a strategic investment alongside, with Murali Venkatesan of Danaher Ventures joining the board. Automata previously raised a $40M round led by Dimension in October 2023.

Automata was founded in London in 2015 and initially sold Eva, a configurable desktop robot arm for automating repetitive manual tasks in any industry. TechCrunch's October 2023 profile reports that the company concluded serving smaller, individualized use cases would not scale into a meaningful business, so it pivoted to sectors on the brink of an automation revolution, focusing on genomics and cell biology labs. The new 'Automata 2.0' stack couples LINQ, a cloud platform for designing and running workflows, with the modular LINQ robotic bench that moves labware between instruments.

Automata's pivot attracted a customer roster including AstraZeneca, UK NHS trusts and the Francis Crick Institute by October 2023, when it raised a $40M round led by Dimension. On January 29, 2026 the company announced a $45M Series C — again led by Dimension, joined by Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First — alongside a strategic partnership with Danaher under which Beckman Coulter Life Sciences and Molecular Devices instruments integrate into LINQ, with Danaher Ventures' Murali Venkatesan joining the board.

As of late January 2026 Automata was scaling: it says five top pharma companies are customers, with repeat deployments on some of the industry's largest automation projects, and the new capital will fund larger deployments, global engineering and customer-success growth, and the next version of its closed-loop experimentation software for AI-driven drug discovery. Revenue and profitability are undisclosed.

Full-lab automation outflanks a single robot arm: LINQ orchestrates instruments the lab already owns, so the workflow — not one task — is the product.

Danaher is a distribution shortcut: Beckman Coulter Life Sciences and Molecular Devices instruments now integrate into LINQ, handing Automata an installed base it never had to sell.

The pivot came from evidence, not panic: Automata's own experience selling small, individualized use cases showed the business would not scale before it rebuilt for genomics and cell biology labs.

AI made physical labs the bottleneck: with computational biology racing ahead, 'programmable, repeatable, AI-ready' wet labs became an infrastructure category pharma budgets would fund.

Partial automation competes on price per task; Automata won by making the whole lab the product, so every instrument a customer already owns is a reason to buy the platform.

As of January 29, 2026, Automata was spending a $45M Series C to scale customer deployments, grow engineering and customer-success teams globally, and build the next iteration of its closed-loop experimentation software. The Danaher partnership puts Beckman Coulter Life Sciences and Molecular Devices instruments inside LINQ and seats Danaher Ventures on the board. Automata says five top pharma companies are customers with repeat deployments, but no revenue is disclosed, and whether one platform can capture a fragmented wet-lab market was still being tested.